Business context and reporting period
Arvinas, Inc. is a clinical-stage biotechnology company developing PROTAC protein degraders. This unaudited Form 10-Q covers the three months ended March 31, 2024; comparisons are with the three months ended March 31, 2023, unless otherwise stated. The company has no approved products and has not generated product-sales revenue.
Key programs include vepdegestrant (ARV-471) for breast cancer, ARV-766 and bavdegalutamide for prostate cancer, ARV-102 for neurodegenerative disease, and preclinical ARV-393. Vepdegestrant is partnered with Pfizer; Arvinas reported entering into a Novartis transaction for ARV-766 and its preclinical AR-V7 program in April 2024, after quarter-end.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | $25.3 million | $32.5 million |
| Research and development expense | $84.3 million | $95.3 million |
| General and administrative expense | $24.3 million | $24.9 million |
| Operating loss | $83.3 million | $87.7 million |
| Net loss | $69.4 million | $81.9 million |
| Net loss per share, basic and diluted | $0.97 | $1.54 |
| Net cash used in operating activities | $97.5 million | $91.2 million |
| Cash, cash equivalents and restricted cash | $93.5 million | $317.2 million at Dec. 31, 2023 |
| Marketable securities | $1,081.3 million | $949.3 million at Dec. 31, 2023 |
| Long-term debt outstanding | $0.9 million | $1.0 million at Dec. 31, 2023 |
Cash, cash equivalents, restricted cash and marketable securities totaled approximately $1.2 billion at March 31, 2024. Current assets were $1,190.3 million and current liabilities were $240.8 million. The filing does not report a meaningful product gross margin; revenue is from collaborations and licenses.
Interest income, net, increased to $14.0 million from $7.6 million, reflecting higher rates and a higher average investment balance. Comprehensive loss was $70.7 million, including $1.3 million of unrealized losses on available-for-sale securities. Stock-based compensation expense was $18.6 million.
Material changes versus the prior comparable period
- Revenue fell $7.2 million, primarily due to lower revenue under the Pfizer vepdegestrant collaboration and the conclusion of the Genentech performance period; increases from Bayer and Pfizer research collaborations partly offset the decline. The 2023 comparison was also affected by changes in estimated collaboration performance periods.
- R&D expense declined $11.0 million, mainly from lower AR- and ER-program clinical trial and drug-manufacturing costs, partly offset by increased personnel and infrastructure costs.
- Net loss narrowed by $12.5 million, while loss per share narrowed to $0.97 from $1.54. Weighted-average shares increased to 71.7 million from 53.3 million.
- Operating cash use increased by $6.3 million. Investing activities used $127.8 million versus providing $138.6 million in Q1 2023, principally reflecting purchases and maturities of marketable securities. The decline in cash and cash equivalents was accompanied by higher marketable securities.
Outlook, commentary and risks
- Management estimates existing cash, cash equivalents, restricted cash and marketable securities will fund planned operating expenses and capital requirements into 2027. This estimate depends on assumptions that may prove incorrect; the company expects continued operating losses and negative operating cash flows and may require additional financing.
- Management expected top-line VERITAC-2 Phase 3 data in the second half of 2024 and expected to determine the recommended palbociclib dose for the VERITAC-3 study in the second half of 2024. These are forward-looking expectations, not assured outcomes.
- In April 2024, Novartis agreed to pay an aggregate $150.0 million upfront for the ARV-766 license and AR-V7 asset, subject to customary closing conditions, including U.S. antitrust review. Arvinas is also eligible for up to $1.01 billion in ARV-766 milestones and tiered royalties; these contingent amounts are not guaranteed.
- FDA granted Fast Track designation for vepdegestrant in a specified breast cancer setting. Arvinas initiated first-in-human dosing of ARV-102 in Q1 and said it planned to initiate a Phase 1 trial of ARV-393 in Q2 2024.
- The company accrued $15.2 million for a contract dispute, compared with $7.0 million at March 31, 2023. The possible loss range cannot currently be estimated; the accrual is management’s best estimate. Arvinas reported no current material litigation or legal proceedings.
- Key risks include clinical and regulatory uncertainty, reliance on third-party CROs and manufacturers, financing needs, and potential disruption from foreign supplier restrictions or regulatory changes, including proposed U.S. legislation concerning certain biotechnology suppliers in China. A new or revised risk factor highlights third-party trial execution and foreign vendor dependence.
- A planned lease for approximately 160,000 square feet of laboratory and office space is expected to be occupied in 2025; base rent is expected to range from $7.7 million to $8.8 million annually over ten years.
Important facts for investors to verify
- Whether the Novartis transaction closed, when the $150.0 million upfront payment was received, and how the transition of ARV-766 development affects Arvinas’s costs and pipeline.
- VERITAC-2 data timing and results, VERITAC-3 dose selection, and progress and safety findings for ARV-102 and ARV-393.
- Whether cash-burn trends and collaboration receipts support management’s stated runway into 2027; the filing cautions that this estimate is assumption-dependent.
- Developments in the contract dispute, including any resolution, payments, or change in the accrued estimate.
- Future clinical-trial execution, manufacturing access, and any resulting delays or costs, particularly involving third-party and foreign vendors.
- Share dilution from equity awards or future financing; the company had 68.3 million common shares outstanding at March 31, 2024 and 68,431,891 as of May 3, 2024.